Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

BJU International

Volumn 105, Issue 4, 2010, Pages 502-507

  Roehrborn, Claus G ^a   Kaminetsky, Jed C ^b   Auerbach, Stephen M ^c   Montelongo, Rafael Martínez ^e   Elion Mboussa, Albert ^d   Viktrup, Lars ^d  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c California Professional Research   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Bladder capacity; Peak urinary flow; Phosphodiesterase type 5 inhibitors; Tadalafil; Voiding efficiency

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; POST HOC ANALYSIS; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; SEXUAL BEHAVIOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE FLOW RATE; UROFLOWMETRY;

AGED; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; TREATMENT OUTCOME; URINATION; URODYNAMICS;

EID: 76149134714     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08822.x     Document Type: Article

References (25)

1. Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993 42 : 663 671
2. Norman RW, Nickel JC, Fish D, Pickett SN. 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994 74 : 542 550
3. American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Guideline Update Panel. Clinical Guidelines: Management of BPH ('03/updated'06). Available at: http://www.auanet.org/content/guidelines-and-quality-care/ clinical-guidelines.cfm?sub=bph. Accessed June 2009
4. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 2398
5. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003 44 : 637 649
6. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008 180 : 1228 1234
7. McVary KT, Monnig W, Camps JL Jr, Young JM, van den Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007 177 : 1071 1077
8. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007 177 : 1401 1407
9. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008 53 : 1236 1244
10. Roehrborn CG. Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol 2004 6 : 121 127
11. Uckert S, Sormes M, Kedia G et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008 71 : 526 530
12. Palea S, Rekik M, Rischmann P, Botto H, Lluel P. Tadalafil exerts an additive effect on alfuzosin-induced relaxation in pre-contracted human isolated prostatic adenoma. J Urol 2008 179 (Suppl. 454 (abstract)
13. Filippi S, Morelli A, Sandner P et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007 148 : 1019 1029
14. Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007 178 : 2040 2044
15. Ehren I, Iversen H, Jansson O, Adolfsson J, Wiklund NP. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 1994 44 : 683 687
16. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003 170 : 659 663
17. Berger AP, Deibl M, Leonhartsberger N et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005 96 : 1073 1078 (Pubitemid 41531417)
18. de la Rosette J, Alivizatos G, Madersbacher S et al. Guidelines on Benign Prostatic hyperplasia (updated March 2004). Available at: http://www.uro.at/mm/ mm007/EAU-BPH.pdf. Accessed June 2009
19. Sanofi Aventis. Uroxatral Prescribing Information 2009. Available at: http://products.sanofi-aventis.us/uroxatral/uroxatral.pdf. Accessed June 2009
20. Boehringer Ingelheim Pharmaceuticals. Flomax Prescribing Information 2009. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/ Flomax+Caps/Flomax.pdf. Accessed June 2009
21. Kraus S, Dmochowski RR, Roehrborn C, Kaminetsky J, Xu L, Klise S. Urodynamic Effects of Tadalafil 20 Mg Once Daily Versus Placebo in Men with Signs and Symptoms of Benign Prostatic Hyperplasia. Eur Urol Suppl 2009 8 : 469
22. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 154 : 1770 1774
23. Fabricius PG, Weizert P, Dunzendorfer U, Hannaford JM, Maurath C. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Prostate Suppl 1990 3 : 85 93
24. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998 51 : 892 900 (Pubitemid 28240845)
25. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med 2006 354 : 1667 1669